MENU
+Compare
NGNE
Stock ticker: NASDAQ
AS OF
Jan 23, 01:13 PM (EDT)
Price
$15.64
Change
-$0.31 (-1.94%)
Capitalization
236.93M

NGNE Neurogene Forecast, Technical & Fundamental Analysis

Industry Biotechnology
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for NGNE with price predictions
Jan 08, 2025

Momentum Indicator for NGNE turns negative, indicating new downward trend

NGNE saw its Momentum Indicator move below the 0 level on January 07, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In of the 88 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NGNE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NGNE advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.724) is normal, around the industry mean (15.076). P/E Ratio (0.000) is within average values for comparable stocks, (88.202). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.833). NGNE has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (222.222) is also within normal values, averaging (264.879).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NGNE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NGNE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NGNE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

NGNE is expected to report earnings to fall 25.00% to -2 cents per share on November 14

Neurogene NGNE Stock Earnings Reports
Q3'23
Est.
$-0.03
Q2'23
Est.
$-0.04
Q1'23
Missed
by $0.04
Q4'22
Missed
by $0.05
Q3'22
Beat
by $0.06
The last earnings report on August 16 showed earnings per share of -3 cents, meeting the estimate of -3 cents. With 32.61K shares outstanding, the current market capitalization sits at 236.93M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
535 W 24th Street
Phone
+1 855 508-3568
Employees
91
Web
https://www.neurogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WBIGX27.300.21
+0.78%
William Blair International Growth N
DFMIX35.370.19
+0.54%
Davidson Multi-Cap Equity I
VSNGX66.53-0.07
-0.11%
JPMorgan Mid Cap Equity I
RYRIX55.71-0.14
-0.25%
Rydex Retailing Inv
PIGRX13.76-0.08
-0.58%
Putnam International Value C

NGNE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with BRNS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then BRNS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
-4.03%
BRNS - NGNE
51%
Loosely correlated
+7.14%
RNAZ - NGNE
48%
Loosely correlated
-0.85%
SNDX - NGNE
40%
Loosely correlated
+2.41%
ZNTL - NGNE
39%
Loosely correlated
+0.44%
BPTSY - NGNE
38%
Loosely correlated
N/A
More